This is a working overview of reconstitution, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-25. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Frydman RB, Tomaro ML, Frydman B (1972). "Pyrrolooxygenase: its action on tryptophan-containing enzymes and peptides". Biochim. Biophys. Acta. 284 (1): 80–9. doi:10.1016/0005-2744(72)90047-2. PMID 4403729.
Actinic granuloma (O'Brien granuloma) Annular elastolytic giant cell granuloma (giant cell elastophagocytosis, Meischer's granuloma, Miescher's granuloma of the face) Annular sarcoidosis Benign cephalic histiocytosis (histiocytosis with intracytoplasmic worm-like bodies) Congenital self-healing reticulohistiocytosis (Hashimoto–Pritzker disease, Hashimoto–Pritzker syndrome) Erythrodermic sarcoidosis Generalized eruptive histiocytoma (eruptive histiocytoma, generalized eruptive histiocytosis) Generalized granuloma annulare Giant cell reticulohistiocytoma (solitary reticulohistiocytoma, solitary reticulohistiocytosis) Granuloma annulare in HIV disease Granuloma multiforme (Mkar disease, granuloma multiforme (Leiker)) Hand–Schüller–Christian disease Heerfordt's syndrome Hereditary progressive mucinous histiocytosis Hypopigmented sarcoidosis Ichthyosiform sarcoidosis Indeterminate cell histiocytosis Interstitial granulomatous drug reaction Langerhans cell histiocytosis (histiocytosis X) Letterer–Siwe disease Localized granuloma annulare Löfgren syndrome Lupus pernio Morpheaform sarcoidosis Mucosal sarcoidosis Multicentric reticulohistiocytosis Necrobiotic xanthogranuloma (necrobiotic xanthogranuloma with paraproteinemia) Non-X histiocytosis Papular sarcoid Papular xanthoma Patch-type granuloma annulare (macular granuloma annulare) Perforating granuloma annulare Progressive nodular histiocytosis Reticulohistiocytoma Scar sarcoid (sarcoidosis in scars) Sea-blue histiocytosis Subcutaneous granuloma annulare (deep granuloma annulare, pseudorheumatoid nodule) Subcutaneous sarcoidosis (Darier–Roussy disease, Darier–Roussy sarcoid) Systemic sarcoidosis Ulcerative sarcoidosis Xanthoma disseminatum (disseminated xanthosiderohistiocytosis, Montgomery syndrome)
=== Theobromine and oxalate === Chocolate may be a factor for heartburn in some people because one of its constituents, theobromine, may affect the esophageal sphincter muscle in a way that permits stomach acids to enter the esophagus. Theobromine poisoning is an overdosage reaction to the bitter alkaloid, which happens more frequently in domestic animals than humans. However, daily intake of 50–100 g cocoa (0.8–1.5 g theobromine) by humans has been associated with sweating, trembling, and severe headache. Chocolate and cocoa contain moderate to high amounts of oxalate, which may increase the risk of kidney stones.
Britain declared war on Germany on 4 August 1914. The next day, General - later Field Marshal - Haig, who had been central to Haldane's reforms and was then commanding First Corps, recorded in his diary that Field Marshal Kitchener did 'not appreciate the progress made by the Territorial Force towards efficiency', The subsequent day, the 6th, Kitchener took up his post as Secretary of State for War announcing that morning 'He could take no account of anything but regular soldiers'. He went on to denounce the Territorial Force as 'a few hundred thousand young men, officered by middle-aged professional men who were allowed to put on uniform and play at soldiers.' Nevertheless, by 9 August, the Army Council, under Kitchener's direction, agreed that TF units volunteering en bloc for overseas service should be sent to France, while Kitchener set in hand the machinery for the recruiting of an entirely separate 'New Army' of what came to be known as Kitchener units, in parallel with the expansion of the Territorial Force. These New Army units were given priority for equipment, recruits and training over the Territorials for the bulk of the war. Kitchener justified this, during the first few months of the war, on the grounds that the Territorial Force should focus mostly on home defence.
Sources: en.wikipedia.org
=== Legal status === THC, along with its double bond isomers and their stereoisomers, is one of only three cannabinoids scheduled by the UN Convention on Psychotropic Substances (the other two are dimethylheptylpyran and parahexyl). It was listed under Schedule I in 1971, but reclassified to Schedule II in 1991 following a recommendation from the World Health Organization (WHO). Based on subsequent studies, the WHO has recommended the reclassification to the less-stringent Schedule III. Cannabis as a plant is scheduled by the Single Convention on Narcotic Drugs (Schedule I and IV). It is specifically still listed under Schedule I by US federal law under the Controlled Substances Act for having "no accepted medical use" and "lack of accepted safety". However, dronabinol, a pharmaceutical form of THC, has been approved by the FDA as an appetite stimulant for people with AIDS and an antiemetic for people receiving chemotherapy under the trade names Marinol and Syndros. In 2003, the WHO Expert Committee on Drug Dependence recommended transferring THC to Schedule IV of the convention, citing its medical uses and low abuse and addiction potential. In 2019, the Committee recommended transferring Δ9-THC to Schedule I of the Single Convention on Narcotic Drugs of 1961, but its recommendations were rejected by the United Nations Commission on Narcotic Drugs.
A lack of economy of size: as most fine chemicals are produced in quantities of less than a few 10 tons per year in multipurpose plants, there is little or no economy of size. The reactor trains of these plants are similar throughout the industry. Regardless of the size of the companies, their main constituents, the reaction vessels, have a median size of 4–6 m3 (140–210 cubic feet). Various products are made throughout a year in campaigns. Therefore, the unit cost per m3 per hour rarely varies with the size of the company. A dichotomy between ownership and management: the company's shares are listed on stock exchanges, and their performance is scrutinized by the financial community. Postponement of a single important shipment can affect a quarterly result. In the small and mid-sized companies, the owners are typically the major shareholders, often members of the same family. Their shares are not traded publicly and fluctuations in their financial performance are more easily coped with. Complicated business processes: flexibility and responsiveness are in jeopardy. Customer complaints, for instance, are difficult to resolve in a straightforward manner. A heterogeneous portfolio of small companies, accumulated over time through M&A activities. The key functions, such as production, R&D, and M&S, are located on different sites, often in different countries. Cohabitation with other units. A comprehensive list of about 1400 fine chemical companies (including traders) can be found in the "event catalogue" of the CPhI exhibition.
== Adverse effects == The most commonly reported side effects of tapentadol therapy are constipation, nausea, vomiting, headaches, loss of appetite, drowsiness, dizziness, itching, dry mouth, and sweating. Tapentadol has also been noted to induce feelings of relaxation and euphoria, and it may cause serious side effects such as respiratory depression, serotonin syndrome, addiction and substance dependence. Several studies have found that tapentadol causes less constipation and nausea compared with oxycodone. It has been noted that due to this, treatment adherence may be improved, with fewer people discontinuing tapentadol (when compared with oxycodone). Tapentadol has been demonstrated to reduce the seizure threshold in patients. Tapentadol should be used cautiously in patients with a history of seizures, and in patients who are also taking one or more other drugs which have also been demonstrated to reduce the seizure threshold. Patients at high risk include those using other serotogenic and adrenergic medications, as well as patients with head trauma, metabolic disorders, and those in alcohol and/or drug withdrawals. Tapentadol has been demonstrated to potentially produce hypotension (low blood pressure), and should be used with caution in patients with low blood pressure, and patients who are taking one or more other medications which are also known to reduce blood pressure.
Responses lasted for at least six months in 78% of responders. Because the clinical trial was fairly small, Merck is obligated to conduct further post-marketing studies to ensure that the results are valid. Pembrolizumab was granted orphan drug designation for small-cell lung cancer in October 2017. In June 2018, the US FDA approved pembrolizumab for use in both advanced cervical cancer for PD-L1 positive patients and for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy. In August 2018, the US FDA updated the prescribing information for pembrolizumab to require the use of an FDA-approved companion diagnostic test to determine PD-L1 levels in tumor tissue from patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible. On 16 August 2018, the FDA approved the Dako PD-L1 IHC 22C3 PharmDx Assay (Dako North America, Inc.) as a companion diagnostic to select patients with locally advanced or metastatic urothelial carcinoma who are cisplatin-ineligible for treatment with pembrolizumab. The 22C3 assay determines PD-L1 expression by using a combined positive score (CPS) assessing PD-L1 staining in tumor and immune cells.
== Structure == Human catalase forms a tetramer composed of four subunits, each of which can be conceptually divided into four domains. The extensive core of each subunit is generated by an eight-stranded antiparallel β-barrel (β1-8), with nearest neighbor connectivity capped by β-barrel loops on one side and α9 loops on the other. A helical domain at one face of the β-barrel is composed of four C-terminal helices (α16, α17, α18, and α19) and four helices derived from residues between β4 and β5 (α4, α5, α6, and α7). Alternative splicing may result in different protein variants.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.